Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results
NYMOZARFEX 15 mg Minimal Treatment of Low Grade Prostate Cancer Leads to Significant Long-Term Reduction in Incidence of Associated Prostate…
Pharmaceuticals, Biotechnology and Life Sciences
NYMOZARFEX 15 mg Minimal Treatment of Low Grade Prostate Cancer Leads to Significant Long-Term Reduction in Incidence of Associated Prostate…
TORONTO, July 25, 2023 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX:AH, OTCQB:ALEAF) (“Aleafia” or the “Corporation”) announces today that the…
Full safety and efficacy data presentation planned for Q4NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) — Intrommune Therapeutics, Inc., a…
CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology…
SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) — Adaptive Research, an organization committed to democratizing clinical trials by providing full-service…
In CARES 310, camrelizumab plus rivoceranib demonstrated statistically significant and clinically meaningful prolonged overall survival and progression-free survival, and improved…
Phase 3 study failed to meet one of the success criteria of the primary objectiveRSV program to be discontinued COPENHAGEN,…
FREMONT, Calif., July 20, 2023 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today…
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed…
WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced…